Results

1–10 of 201 results for Macular Edema

Aflibercept 8 mg in Diabetic Macular Edema: 156-Week Results From the PHOTON Extension Study
Eric W Schneider, MD
Updates from the Field
2025
VERONA: End-of-Study Results From a Phase 2 Trial of EYP-1901 (Vorolanib Intravitreal Insert) vs Aflibercept for Diabetic Macular Edema
Yasha S Modi, MD
Updates from the Field
2025
Benefits and Value of Treatment for Diabetic Macular Edema
Paul Hahn, MD, PhD, FASRS
Annual Meeting Talks
2022
Phase 2a Study of CU06-1004, an Oral Endothelial Dysfunction Blocker for the Treatment of Diabetic Macular Edema
Victor Hugo Gonzalez, MD
Updates from the Field
2024
Efficacy, Safety, and Durability of Faricimab in Macular Edema Due to Retinal Vein Occlusion:72-Week Results From the Phase 3 BALATON and COMINO Trials
Carl J Danzig, MD
Updates from the Field
2024
Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Updates from the Field
2024
Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy
Michael J Allingham, MD, PhD
Annual Meeting Talks
2022
Factors Associated With Fluctuations in Central Subfield Thickness in Patients With Diabetic Macular Edema Using 2 Clinical Trial Databases
Matthew Starr, MD
Annual Meeting Talks
2022
Angiopoietin-2 Signaling and Vascular Stability With Faricimab in Diabetic Macular Edema
Karl G. Csaky, MD, PhD
Annual Meeting Talks
2022
Dropless Vitrectomy Surgery for Epiretinal Membranes: Efficacy and Safety Compared to Standard of Care
K. V. Chalam, MD, PhD, MBA, FRCS(C), FASRS
Annual Meeting Talks
2022